Vaxcyte, Inc.
- Last sale
- Nov 12, 2026 · -5.76%
- Market cap
- $10.24B
- 158.3M shares
- Filings
- 772
—
—
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−55.2% FY25 yoy
- $10.24B
- —
- —
- 4.1×
- -6.54%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $794,306,000 | reported | |
| FY 2024 | 2024-12-31 | $476,644,000 | reported | |
| FY 2023 | 2023-12-31 | $332,341,000 | reported | |
| FY 2022 | 2022-12-31 | $169,451,000 | reported | |
| FY 2021 | 2021-12-31 | $78,411,000 | reported | |
| FY 2020 | 2020-12-31 | $73,564,000 | reported | |
| FY 2019 | 2019-12-31 | $45,607,000 | reported | |
| FY 2018 | 2018-12-31 | $30,145,000 | reported |
Segments
Geography
LineFY2025ShareChange
SWITZERLAND$217.70M85%+38.5%
UNITED STATES$39.70M15%−2.7%
Total$257.37M
Biological products, except diagnostic substances
Vaxcyte, Inc. is the 15th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
HALOHalozyme Therapeutics, Inc.$1.4B37.6%22.7%$11.5BTECHBio-Techne Corp$1.2B0.4%15.0%$11.4BQGENQiagen N.V.$2.1B5.7%20.3%$10.9BKYMRKymera Therapeutics, Inc.$39.2M16.7%794.0%$10.9BRGENRepligen Corp$738.3M16.4%6.6%$10.7B
PCVXVaxcyte, Inc. (this company)———$10.2B
KRYSKrystal Biotech, Inc.$389.1M33.9%52.6%$9.1BTWSTTwist Bioscience Corp$459.4M22.0%28.3%$7.8BIMVTImmunovant, Inc.———$7.3BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Vaxcyte, Inc. · CIK 1649094 · Engraved from SEC EDGAR